Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many incidences of assault have been committed against community pharmacy staff in the last year.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The data related to crime, including assault and theft, in community pharmacies is not held by the Department but could be obtained from individual police departments through Freedom of Information requests. These are matters for the police and criminal justice system. Community pharmacy staff are considered emergency workers under the Assaults on Emergency Workers (Offences) Act 2018 which provides for increased sentencing powers.
Community pharmacies are private businesses that are commissioned to provide National Health Service pharmaceutical services and are legally responsible for the health and safety of their staff.
Pharmacies are by law required to keep controlled drugs, those most likely to be abused or that pose a risk of diversion from a legal supply route, in a locked safe, cabinet or room which is constructed to prevent unauthorised access to the drugs.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to monitor the safety of community pharmacies.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The data related to crime, including assault and theft, in community pharmacies is not held by the Department but could be obtained from individual police departments through Freedom of Information requests. These are matters for the police and criminal justice system. Community pharmacy staff are considered emergency workers under the Assaults on Emergency Workers (Offences) Act 2018 which provides for increased sentencing powers.
Community pharmacies are private businesses that are commissioned to provide National Health Service pharmaceutical services and are legally responsible for the health and safety of their staff.
Pharmacies are by law required to keep controlled drugs, those most likely to be abused or that pose a risk of diversion from a legal supply route, in a locked safe, cabinet or room which is constructed to prevent unauthorised access to the drugs.
Asked by: Cat Smith (Labour - Lancaster and Fleetwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the mental health and wellbeing of student nurses in England.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The health and wellbeing of all National Health Service staff is taken seriously, and there is a wide range of support in place to aid the health and wellbeing of NHS staff. This includes a Health and Wellbeing Guardian role to ensure board level scrutiny, and that there are tools and resources to support line managers in holding meaningful conversations with staff to discuss their emotional and psychological health and wellbeing. The support package also includes access to regional mental health and wellbeing hubs.
In 2023, NHS England published a strategy to grow occupational health and wellbeing, setting out a roadmap for the NHS and partner organisations to work together to develop and invest in occupational health and wellbeing services for staff over the next five years. To ensure there is a long term sustainable approach to supporting staff, the NHS Long Term Workforce Plan has tasked integrated care boards with developing and implementing plans to invest in occupational health and wellbeing services.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department for Education:
To ask the Secretary of State for Education, what steps she is taking to ensure that there are sufficient qualified staff to deal with Education, Health and Care Plans.
Answered by David Johnston - Parliamentary Under-Secretary (Department for Education)
As part of the reforms to the special educational needs and disabilities (SEND) system, the department is currently testing measures to deliver a nationally consistent Education, Health and Care (EHC) plan system and improve the quality and speed with which support is put in place. The department is taking steps to increase the capacity of the workforce supporting children and young people with SEND, but it is the responsibility of individual employers, including local authorities, schools and healthcare settings, to plan their staffing levels in line with their local service priorities.
Educational psychologists have a critical role, providing statutory input into EHC plan assessments and advising the school workforce on how to support children and young people with SEND. The department is investing over £21 million to train 400 more educational psychologists from 2024.
Since 2020, the department has increased the number of educational psychologist trainees that we fund to over 200, from 160 per year. As these larger cohorts complete their studies, they will join the workforce to support local authority educational psychology services, including contributing to EHC plan assessments.
Local authority caseworkers play a vital role in supporting families to navigate the system and ensuring they have good experiences, including through the EHC plan process. To build capacity, the department is providing legal training for local authority caseworkers this year and will consider new guidance to deliver a responsive and supportive casework service.
The department is committed to a joint Department for Education and Department of Health and Social Care approach to SEND workforce planning. The departments aim to complete this by 2025. This will build on the NHS Long Term Workforce Plan published in June 2023 which sets out the steps the NHS and its partners need to take to deliver an NHS workforce that meets the changing needs of the population over the next 15 years.
To support the supply of more speech and language therapists and occupational therapists to the NHS, since September 2020 all eligible undergraduate and postgraduate degree students have been able to apply for a non-repayable training grant of a minimum of £5,000 per academic year, with further financial support available for childcare, accommodation, and travel costs.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the adequacy of funding provided to the Medicines and Healthcare products Regulatory Agency.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices, and blood components for transfusion in the United Kingdom. It achieves this through the expertise of its staff, and its assets of ground-breaking science, innovative regulation, and real-world data.
Ministers receive regular updates on the performance of the MHRA. The agency is taking significant steps to assess licensing applications within the shortest time possible. It is working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. As an effective regulator, it is committed to the highest of standards of performance, and delivering the right outcomes for patients and public health. These changes are already resulting in improvements.
The Department holds the MHRA to account for their work, including their performance and the impact of any organisational changes, through regular established mechanisms including quarterly and annual accountability reviews. The minutes of the latest Annual Accountability Review with the MHRA are available at the following link:
The MHRA also publishes performance figures each month, and annually through their annual report and accounts. As set out in its 2023-26 Corporate Plan, the MHRA is committed to delivering predictable, optimised, and sustainable services, across all functions.
As part of the 2023 Spring Budget, the MHRA also received £10 million of additional funding. This is to support the acceleration of routes for bringing innovative medical products developed in the UK onto the market, allowing the MHRA to capitalise on the expertise and decision-making of trusted regulatory partners. The Government is committed to supporting the MHRA to meet its statutory obligations.
The Department receives regular feedback from a wide range of stakeholders. In 2023 the Department did receive representations from the scientific community, and industry, expressing concern about delays in the MHRA’s approvals of clinical trials. The MHRA has since improved its performance in this area, and there are currently no delays in approving clinical trials.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to (a) monitor and (b) report on the performance of the Medicines and Healthcare Products Regulatory Agency.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices, and blood components for transfusion in the United Kingdom. It achieves this through the expertise of its staff, and its assets of ground-breaking science, innovative regulation, and real-world data.
Ministers receive regular updates on the performance of the MHRA. The agency is taking significant steps to assess licensing applications within the shortest time possible. It is working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. As an effective regulator, it is committed to the highest of standards of performance, and delivering the right outcomes for patients and public health. These changes are already resulting in improvements.
The Department holds the MHRA to account for their work, including their performance and the impact of any organisational changes, through regular established mechanisms including quarterly and annual accountability reviews. The minutes of the latest Annual Accountability Review with the MHRA are available at the following link:
The MHRA also publishes performance figures each month, and annually through their annual report and accounts. As set out in its 2023-26 Corporate Plan, the MHRA is committed to delivering predictable, optimised, and sustainable services, across all functions.
As part of the 2023 Spring Budget, the MHRA also received £10 million of additional funding. This is to support the acceleration of routes for bringing innovative medical products developed in the UK onto the market, allowing the MHRA to capitalise on the expertise and decision-making of trusted regulatory partners. The Government is committed to supporting the MHRA to meet its statutory obligations.
The Department receives regular feedback from a wide range of stakeholders. In 2023 the Department did receive representations from the scientific community, and industry, expressing concern about delays in the MHRA’s approvals of clinical trials. The MHRA has since improved its performance in this area, and there are currently no delays in approving clinical trials.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has received representations from the scientific community on the efficiency of the Medicines and Healthcare products Regulatory Agency.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices, and blood components for transfusion in the United Kingdom. It achieves this through the expertise of its staff, and its assets of ground-breaking science, innovative regulation, and real-world data.
Ministers receive regular updates on the performance of the MHRA. The agency is taking significant steps to assess licensing applications within the shortest time possible. It is working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. As an effective regulator, it is committed to the highest of standards of performance, and delivering the right outcomes for patients and public health. These changes are already resulting in improvements.
The Department holds the MHRA to account for their work, including their performance and the impact of any organisational changes, through regular established mechanisms including quarterly and annual accountability reviews. The minutes of the latest Annual Accountability Review with the MHRA are available at the following link:
The MHRA also publishes performance figures each month, and annually through their annual report and accounts. As set out in its 2023-26 Corporate Plan, the MHRA is committed to delivering predictable, optimised, and sustainable services, across all functions.
As part of the 2023 Spring Budget, the MHRA also received £10 million of additional funding. This is to support the acceleration of routes for bringing innovative medical products developed in the UK onto the market, allowing the MHRA to capitalise on the expertise and decision-making of trusted regulatory partners. The Government is committed to supporting the MHRA to meet its statutory obligations.
The Department receives regular feedback from a wide range of stakeholders. In 2023 the Department did receive representations from the scientific community, and industry, expressing concern about delays in the MHRA’s approvals of clinical trials. The MHRA has since improved its performance in this area, and there are currently no delays in approving clinical trials.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she plans to take steps to help increase productivity in the Medicines and Healthcare products Regulatory Agency.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices, and blood components for transfusion in the United Kingdom. It achieves this through the expertise of its staff, and its assets of ground-breaking science, innovative regulation, and real-world data.
Ministers receive regular updates on the performance of the MHRA. The agency is taking significant steps to assess licensing applications within the shortest time possible. It is working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. As an effective regulator, it is committed to the highest of standards of performance, and delivering the right outcomes for patients and public health. These changes are already resulting in improvements.
The Department holds the MHRA to account for their work, including their performance and the impact of any organisational changes, through regular established mechanisms including quarterly and annual accountability reviews. The minutes of the latest Annual Accountability Review with the MHRA are available at the following link:
The MHRA also publishes performance figures each month, and annually through their annual report and accounts. As set out in its 2023-26 Corporate Plan, the MHRA is committed to delivering predictable, optimised, and sustainable services, across all functions.
As part of the 2023 Spring Budget, the MHRA also received £10 million of additional funding. This is to support the acceleration of routes for bringing innovative medical products developed in the UK onto the market, allowing the MHRA to capitalise on the expertise and decision-making of trusted regulatory partners. The Government is committed to supporting the MHRA to meet its statutory obligations.
The Department receives regular feedback from a wide range of stakeholders. In 2023 the Department did receive representations from the scientific community, and industry, expressing concern about delays in the MHRA’s approvals of clinical trials. The MHRA has since improved its performance in this area, and there are currently no delays in approving clinical trials.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase the capacity of the Medicines and Healthcare products Regulatory Agency.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices, and blood components for transfusion in the United Kingdom. It achieves this through the expertise of its staff, and its assets of ground-breaking science, innovative regulation, and real-world data.
Ministers receive regular updates on the performance of the MHRA. The agency is taking significant steps to assess licensing applications within the shortest time possible. It is working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. As an effective regulator, it is committed to the highest of standards of performance, and delivering the right outcomes for patients and public health. These changes are already resulting in improvements.
The Department holds the MHRA to account for their work, including their performance and the impact of any organisational changes, through regular established mechanisms including quarterly and annual accountability reviews. The minutes of the latest Annual Accountability Review with the MHRA are available at the following link:
The MHRA also publishes performance figures each month, and annually through their annual report and accounts. As set out in its 2023-26 Corporate Plan, the MHRA is committed to delivering predictable, optimised, and sustainable services, across all functions.
As part of the 2023 Spring Budget, the MHRA also received £10 million of additional funding. This is to support the acceleration of routes for bringing innovative medical products developed in the UK onto the market, allowing the MHRA to capitalise on the expertise and decision-making of trusted regulatory partners. The Government is committed to supporting the MHRA to meet its statutory obligations.
The Department receives regular feedback from a wide range of stakeholders. In 2023 the Department did receive representations from the scientific community, and industry, expressing concern about delays in the MHRA’s approvals of clinical trials. The MHRA has since improved its performance in this area, and there are currently no delays in approving clinical trials.
Asked by: Stephen Morgan (Labour - Portsmouth South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to reduce waiting times for mental health services.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
More and more people are getting support with their mental health thanks to investments made through the NHS Long Term Plan. Unfortunately, demand has risen as the impacts of the COVID-19 pandemic and the rise in the cost of living on people’s mental health continues to be felt. This means that some people are facing waiting times that are much longer than we would like.
We are providing record levels of investment and increasing the mental health workforce to expand and transform National Health Service mental health services, to expand access and reduce waiting times. Between 2018/19 and 2023/24, NHS spending on mental health has increased by £4.6 billion in cash terms, as compared to the target of £3.4 billion in cash terms set out at the time of the Long Term Plan. The NHS Long Term Plan committed to grow the mental health workforce by an additional 27,000 staff between 2019/20 and 2023/24. We are making positive progress, delivering two-thirds of this, or 17,000 additional staff, by September 2023, with further significant growth expected by the end of this financial year.
The NHS is also working towards implementing five new waiting time measures for people requiring mental healthcare in both accident and emergency and in the community, for both adults, and children and young people. This includes working towards improving the quality of data that we have on waiting times for people requiring mental healthcare, in both accident and emergency and in the community. NHS England began publishing this new data in 2023 to improve transparency and drive local accountability.